Jolene Kay Berg
YOU?
Author Swipe
View article: Issue Information
Issue Information Open
Aims and Scope: For more than 50 years, clinical pharmacologists, clinical and pharmaceutical researchers, drug development specialists, physicians, nurses, and other medical professionals have relied on The Journal of Clinical Pharmacolog…
View article: Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease
Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease Open
Aims Erythropoiesis‐stimulating agents used to treat anaemia in patients with chronic kidney disease (CKD) have been associated with cardiovascular adverse events. Hepcidin production, controlled by bone morphogenic protein 6 (BMP6), regul…
View article: Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor Open
View article: Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function Open
Hemodialysis resulted in modestly higher exposure to ticagrelor and AR-C124910XX, with no clinically significant effect on PD or tolerability. Accordingly, no dose adjustment is required for hemodialysis patients. Timing of hemodialysis ha…
View article: Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function Open
Many antibiotics require dose adjustments in patients with renal impairment and/or in those undergoing hemodialysis. Omadacycline, the first aminomethylcycline antibiotic in late-stage clinical development, displays activity against a broa…
View article: Issue Information
Issue Information Open
Aims and Scope: For more than 50 years, clinical pharmacologists, clinical and pharmaceutical researchers, drug development specialists, physicians, nurses, and other medical professionals have relied on The Journal of Clinical Pharmacolog…
View article: Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics Open
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel movements that is subtyped as predominantly diarrheal (IBSD), constipating, or mixed/alternating between dia…
View article: Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics Open
Based on the findings of this study, dose adjustments of isavuconazole are unlikely to be required in individuals with RI or in those with ESRD who receive hemodialysis.
View article: Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment Open
Cefiderocol, a new injectable siderophore cephalosporin antibiotic, has promising in vitro and in vivo activity against Gram‐negative bacteria including multidrug‐resistant Pseudomonas aeruginosa, Acinetobacter baumannii , and Klebsiella p…
View article: FP658JTZ-951, A NOVEL HIF-PHD INHIBITOR, DEMONSTRATES INCREASES IN HEMOGLOBIN, IRON MOBILIZATION, REPRODUCIBLE PHARMACOKINETICS, AND SAFETY FOLLOWING ONCE DAILY ADMINISTRATION FOR 15 DAYS IN PATIENTS WITH ANEMIA RECEIVING HEMODIALYSIS
FP658JTZ-951, A NOVEL HIF-PHD INHIBITOR, DEMONSTRATES INCREASES IN HEMOGLOBIN, IRON MOBILIZATION, REPRODUCIBLE PHARMACOKINETICS, AND SAFETY FOLLOWING ONCE DAILY ADMINISTRATION FOR 15 DAYS IN PATIENTS WITH ANEMIA RECEIVING HEMODIALYSIS Open
View article: Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus
Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus Open
Nalbuphine HCl ER tablets can be safely administered to HD patients without dose adjustment up to 240 mg BID and may hold promise in treating uremic pruritus.
View article: Single-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and Its Active Moiety Debio 1452, Administered Intravenously in Healthy Subjects
Single-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and Its Active Moiety Debio 1452, Administered Intravenously in Healthy Subjects Open